Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.50 |
| ▸ | GCGR | P47871 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | FRK | P42685 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.49 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7491106 | 1.00 | MAPK14 (0.59) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL5255543 | 0.84 | MAPK11 (0.52) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL19972125 | 0.83 | MKNK1 (0.51) | MAPK14MAPK11MAPK13MAPK12SRC | |
| SCHEMBL14519385 | 0.83 | MKNK1 (0.51) | MAPK14MAPK11MAPK13MAPK12SRC | |
| SCHEMBL5258469 | 0.82 | MAPK14 (0.69) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL14519418 | 0.82 | MAPK14 (0.69) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL8836383 | 0.82 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL8836207 | 0.82 | MAPK14 (0.59) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL8836352 | 0.82 | KDM4E (0.50) | MAPK14MAPK11 | |
| SCHEMBL14521828 | 0.82 | MAPK14 (0.69) | MAPK14MAPK11MAPK13MAPK12GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091982-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3091982-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9944648-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944648-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944648-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170190703-A9 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190703-A9 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190703-A9 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| EP-3091982-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326179-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-1142890-A1 | AMINOPYRAZOLE DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| CN-1041929-C | Pyrazolitriazines with interleukin-1 and tumour necrosis factor inhibitory activity | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-02-03 | — | — | CN | disclosed |
| US-5670503-A | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR MEDIATED DISEASES SUCH AS INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| US-5624931-A | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-29 | — | — | US | disclosed |
| CN-1120840-A | Pyrazolitriazines with interleukin-1 and tumour necrosis factor inhibitory activity | FUJISAWA PHARAMCEUTICAL CO LTD (JP) | 1996-04-17 | — | — | CN | disclosed |
| US-5478827-A | Inhibits Interleukin-1 and tumor necrosis factor production | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0686156-A1 | PYRAZOLITRIAZINES WITH INTERLEUKIN-1 AND TUMOUR NECROSIS FACTOR INHIBITORY ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-12-13 | — | — | EP | disclosed |
| US-5356897-A | Inhibit the production of Interleukin-1 and tumor necrosis factor; administering for treatment of chronic inflammatory diseases, autoimmune diseases and sepsis-induced organ injury | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-18 | — | — | US | disclosed |
| WO-1994019350-A1 | PYRAZOLITRIAZINES WITH INTERLEUKIN-1 AND TUMOUR NECROSIS FACTOR INHIBITORY ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
| EP-0531901-A2 | Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190703-A9 | ORGANIC COMPOUNDS | PSEN1, CKMT1A; CKMT1B, GSK3A | MAPK14 2412/4885MAPK11 1634/4885MAPK13 2382/4885 |
| US-20160326179-A1 | ORGANIC COMPOUNDS | PSEN1, CKMT1A; CKMT1B, GSK3A | MAPK14 2412/4885MAPK11 1634/4885MAPK13 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.